NASDAQ:MIRA MIRA Pharmaceuticals (MIRA) Stock Price, News & Analysis → He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (From InvestorPlace) (Ad) Free MIRA Stock Alerts $0.66 -0.02 (-2.96%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.63▼$0.7150-Day Range$0.66▼$1.5552-Week Range$0.63▼$7.98Volume74,728 shsAverage Volume48,152 shsMarket Capitalization$9.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get MIRA Pharmaceuticals alerts: Email Address MIRA Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.29Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.62) to ($0.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.21 out of 5 starsMedical Sector898th out of 920 stocksPharmaceutical Preparations Industry417th out of 427 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for MIRA Pharmaceuticals.Read more about MIRA Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.42% of the float of MIRA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMIRA Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MIRA Pharmaceuticals has recently decreased by 2.13%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMIRA Pharmaceuticals does not currently pay a dividend.Dividend GrowthMIRA Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MIRA. Previous Next 1.5 News and Social Media Coverage News SentimentMIRA Pharmaceuticals has a news sentiment score of -0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for MIRA Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for MIRA on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows1 people have added MIRA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MIRA Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 35.16% of the stock of MIRA Pharmaceuticals is held by institutions.Read more about MIRA Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MIRA Pharmaceuticals are expected to grow in the coming year, from ($0.62) to ($0.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MIRA Pharmaceuticals is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MIRA Pharmaceuticals is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMIRA Pharmaceuticals has a P/B Ratio of 3.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MIRA Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchA letter is coming from the "Bureau of the Fiscal Service".Is your bank next? A powerful new trend is spreading like wildfire inside the US financial system. At least 41 banks are already involved. But the Federal Reserve predicts that number will grow fast.See if your bank is involved right here. About MIRA Pharmaceuticals Stock (NASDAQ:MIRA)MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.Read More MIRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MIRA Stock News HeadlinesMay 18 at 3:56 AM | americanbankingnews.comMIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Expected to Earn Q3 2024 Earnings of ($0.26) Per ShareMay 17 at 5:42 AM | americanbankingnews.comZacks Small Cap Weighs in on MIRA Pharmaceuticals, Inc.'s FY2026 Earnings (NASDAQ:MIRA)May 14, 2024 | finance.yahoo.comMIRA Focuses on Potential Game-Changing Drug SubmissionApril 17, 2024 | msn.comMIRA Pharmaceuticals (MIRA) Price Target Decreased by 27.31% to 16.83April 2, 2024 | msn.comFDA clears first digital treatment for depression, but experts caution that research is still earlyApril 2, 2024 | marketwatch.comMIRA Pharmaceuticals Sees Positive Trial Results for Ketamir-2April 2, 2024 | markets.businessinsider.comMira Pharmaceuticals Steps Closer To Ketamir-2 IND Submission After Positive Preclinical ResultsApril 2, 2024 | finance.yahoo.comMIRA Making Strides Toward Breakthrough TreatmentApril 2, 2024 | prnewswire.comMira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND SubmissionMarch 28, 2024 | msn.com‘Ninja,’ Twitch’s biggest streamer, diagnosed with skin cancerMarch 28, 2024 | msn.comClarence Thomas and Samuel Alito dust off 150-year-old Comstock Act to target abortion rightsMarch 21, 2024 | prnewswire.comMIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific AdvisorMarch 18, 2024 | ca.finance.yahoo.comThere are ways to improve the London Stock Exchange crisis, but they’re not prettyMarch 12, 2024 | finance.yahoo.comBaker Hill Nominated for Tech Company of the Year in TechPoint's 25th Annual Mira AwardsMarch 8, 2024 | msn.comALS drug fails large clinical trial and may be withdrawn from marketMarch 8, 2024 | msn.comMedical Marijuana-Focused Mira Pharmaceuticals Stock Surges After Neuropsychiatric Disorders Update - Here's WhyMarch 8, 2024 | investorplace.comWhy Is Mira Pharmaceuticals (MIRA) Stock Up 52% Today?March 1, 2024 | msn.comEl Salvador -India strengthen ties: Adriana Mira unveils path to bilateral cooperationFebruary 23, 2024 | ca.finance.yahoo.comMaternal mental health conditions drive climbing death rate in US, research saysFebruary 6, 2024 | finance.yahoo.comIs MIRA Pharmaceuticals (NASDAQ:MIRA) In A Good Position To Deliver On Growth Plans?February 5, 2024 | finanznachrichten.deMIRA Pharmaceuticals, Inc.: MIRA Pharmaceuticals Provides Corporate UpdateFebruary 5, 2024 | markets.businessinsider.comMIRA Pharmaceuticals Partners Pharmaseed To Conduct Pre-Clinical Studies On KetamirFebruary 5, 2024 | finance.yahoo.comMIRA Pharmaceuticals Provides Corporate UpdateJanuary 30, 2024 | finance.yahoo.comWearable Sensors Market Size Worth USD 11.05 Billion in 2032 | Emergen ResearchJanuary 29, 2024 | msn.comADHD medication recalled due to pill mixupSee More Headlines Receive MIRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MIRA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today5/18/2024Next Earnings (Estimated)9/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MIRA Previous SymbolNASDAQ:MIRA CUSIPN/A CIK1904286 Webmirapharmaceuticals.com Phone737-289-0835FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-293.51% Return on Assets-229.04% Debt Debt-to-Equity RatioN/A Current Ratio5.70 Quick Ratio8.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book3.12Miscellaneous Outstanding Shares14,780,000Free FloatN/AMarket Cap$9.68 million OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Erez Aminov (Age 45)CEO & Chairman Comp: $337.05kMs. Michelle Yanez M.B.A. (Age 51)CFO, Secretary & Treasurer Comp: $338.77kDr. Itzchak Angel Ph.D.Chief Scientific AdvisorKey CompetitorsAeterna ZentarisNASDAQ:AEZSMonopar TherapeuticsNASDAQ:MNPRGalera TherapeuticsNASDAQ:GRTXAvalo TherapeuticsNASDAQ:AVTXElevai LabsNASDAQ:ELABView All CompetitorsInsiders & InstitutionsCross Staff Investments IncBought 383,401 shares on 5/2/2024Ownership: 2.594%Suncoast Equity ManagementBought 40,000 shares on 5/2/2024Ownership: 0.271%Praetorian Wealth Management Inc.Bought 27,500 shares on 4/10/2024Ownership: 0.186%Brian Patrick McnultySold 46,005 sharesTotal: $71,307.75 ($1.55/share)Brian Patrick McnultySold 19,053 sharesTotal: $30,675.33 ($1.61/share)View All Insider TransactionsView All Institutional Transactions MIRA Stock Analysis - Frequently Asked Questions How have MIRA shares performed in 2024? MIRA Pharmaceuticals' stock was trading at $1.05 at the beginning of 2024. Since then, MIRA stock has decreased by 37.6% and is now trading at $0.6550. View the best growth stocks for 2024 here. When is MIRA Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, September 20th 2024. View our MIRA earnings forecast. How were MIRA Pharmaceuticals' earnings last quarter? MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) released its quarterly earnings results on Monday, April, 1st. The company reported ($0.19) earnings per share for the quarter. When did MIRA Pharmaceuticals IPO? MIRA Pharmaceuticals (MIRA) raised $9 million in an IPO on Thursday, August 3rd 2023. The company issued 1,275,000 shares at $7.00 per share. Who are MIRA Pharmaceuticals' major shareholders? MIRA Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cross Staff Investments Inc (2.59%), Suncoast Equity Management (0.27%) and Praetorian Wealth Management Inc. (0.19%). Insiders that own company stock include Brian Patrick Mcnulty and George Cappy. View institutional ownership trends. How do I buy shares of MIRA Pharmaceuticals? Shares of MIRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MIRA) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubThe Presidential candidate you should REALLY be worried aboutStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MIRA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
